Traws Share Price

Traws Share Price

NASDAQ: TRAW | Micro Cap | Healthcare
$0.25
+$0.25 (--%) Last updated on 19 Nov, 2026 | 02:26 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Traws Stock Performance

Open
$0.26
Prev. Close
N/A
Circuit Range
N/A
Day Range
$0.25 - $0.26
Year Range
$0.22 - $3.23
Volume
900
Average Traded
$0.25

Traws Share Price Chart

Line chart of the Traws price trend over the selected period. The price rose overall, ranging from 0.25 to 0.26, ending at 0.25.
$0.25$0.26
L
Show Current Price
H

Traws Stock Fundamentals & Key Indicators

Market Cap
$2.03M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.09
Revenue (TTM)
$2.79B
Return On Equity (TTM)
-989.71%
Profit Margin
246.24%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
14.14%

Traws Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$3.04-$5.40-$5.69-$2.61
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-77.63%-5.37%54.13%

Traws Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.23$2.79
Net Profit-$54.67$6.87
Net Profit Margin-23769.57%246.24%
Income ChangeN/A112.57%

Traws Balance Sheet

All figures in USD Million

Particulars20252024
Non Current Assets2.640.01
Current Assets7.9824.95
Total Assets10.6224.96
Non Current Liabilities0.145.06
Current Liabilities11.1511.53
Total Liabilities11.2556.59
Shareholders' Equity-0.63-31.63

Traws Cash Flow

Annually

All figures in USD Million

Particulars20252024
Operating-18.19-29.79
Investing-2.59-3.65
Financing3.233.98

Corporate Actions

Split
Ex-date: 23 Sep 2024

About Traws

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Traws Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.30
$0.25
-15.17%
Oct 2026
$0.56
$0.29
-51.67%
Sep 2026
$0.56
$0.60
+13.21%
Aug 2026
$0.45
$0.53
+18.04%
Jul 2026
$0.82
$0.45
-45.38%
Jun 2026
$1.47
$0.82
-43.51%
May 2026
$1.45
$1.46
+2.46%
Apr 2026
$1.73
$1.42
-20.67%
Mar 2026
$1.51
$1.79
+9.15%
Feb 2026
$2.04
$1.64
-23.72%
Jan 2026
$1.17
$2.15
+95.45%
Dec 2025
$2.73
$1.10
-59.26%

Traws Share Price FAQs